Frederick G. Vogt Ph.D., Esq.
Net Worth

Last updated:

What is Frederick G. Vogt Ph.D., Esq. net worth?

The estimated net worth of Dr. Frederick G. Vogt Ph.D., Esq. is at least $1,551,420 as of 2 Dec 2024. He owns shares worth $5,220 as insider and has received compensation worth at least $1,546,200 in Iovance Biotherapeutics, Inc..

What is the salary of Frederick G. Vogt Ph.D., Esq.?

Dr. Frederick G. Vogt Ph.D., Esq. salary is $515,400 per year as Interim Pres, Chief Executive Officer, Gen. Counsel & Corporation Sec. in Iovance Biotherapeutics, Inc..

How old is Frederick G. Vogt Ph.D., Esq.?

Dr. Frederick G. Vogt Ph.D., Esq. is 51 years old, born in 1974.

What stocks does Frederick G. Vogt Ph.D., Esq. currently own?

As insider, Dr. Frederick G. Vogt Ph.D., Esq. owns shares in one company:

Company Title Shares Price per share Total value
Iovance Biotherapeutics, Inc. (IOVA) Interim Pres, Chief Executive Officer, Gen. Counsel & Corporation Sec. 2,000 $2.61 $5,220

What does Iovance Biotherapeutics, Inc. do?

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

IOVA logo
IOVA
Iovance Biotherapeutics, Inc.
$2.61

Frederick G. Vogt Ph.D., Esq. insider trading

Iovance Biotherapeutics, Inc.

Transaction Date Security Shares Price per share Total value Source
Option
Restricted Stock Units 10,417 N/A N/A
Option
Common Stock 10,417 N/A N/A
Option
Common Stock 20,834 N/A N/A
Option
Restricted Stock Units 20,834 N/A N/A
Option
Common Stock 10,417 N/A N/A
Option
Common Stock 46,875 N/A N/A
Option
Restricted Stock Units 46,875 N/A N/A
Option
Restricted Stock Units 10,417 N/A N/A
Option
Common Stock 20,835 N/A N/A
Option
Restricted Stock Units 20,835 N/A N/A
Option
Common Stock 10,417 N/A N/A
Option
Restricted Stock Units 10,417 N/A N/A
Option
Restricted Stock Units 20,834 N/A N/A
Option
Common Stock 20,834 N/A N/A
Option
Restricted Stock Units 41,662 N/A N/A
Option
Common Stock 41,662 N/A N/A
Option
Common Stock 20,834 N/A N/A
Option
Restricted Stock Units 20,834 N/A N/A
Option
Restricted Stock Units 20,835 N/A N/A
Option
Common Stock 20,835 N/A N/A
Option
Common Stock 20,834 N/A N/A
Option
Restricted Stock Units 20,834 N/A N/A
Option
Common Stock 20,834 N/A N/A
Option
Restricted Stock Units 20,834 N/A N/A
Option
Common Stock 83,325 N/A N/A
Option
Restricted Stock Units 83,325 N/A N/A
Purchase
Common Stock 1,000 $5.98 $5,980
Purchase
Common Stock 1,000 $6.44 $6,440

Iovance Biotherapeutics key executives

Iovance Biotherapeutics, Inc. executives and other stock owners filed with the SEC: